Jim is an Auckland-based company director who is currently the Chair of Aroa Biosurgery Ltd., Prevar Ltd., Infotools Ltd.,and R J Hills Laboratories Ltd. Mr McLean was previously an Executive Director of Genesis Research and prior to that, a partner with Ernst & Young.
Non Executive Director
Phil is the Founding Partner of Movac, New Zealand’s leading technology investor. He has been actively investing since 1998 and personally invested in all the Movac funds and led investment into over 20 companies. Phil serves on the board of a number of New Zealand technology companies and is also the past Chair of the Angel Association of New Zealand. Phil holds a Bachelor of Business Studies majoring in Accounting, Finance and Information Technology and was awarded a Senior Scholarship from Massey University.
Brian has held senior corporate roles in life sciences and health care companies over the last 20 years. He is a graduate from Massey University with a Bachelor’s degree in Veterinary Science, a Member of the Royal College of Veterinary Surgeons (UK), and holds a Masters degree in Business Administration graduating with distinction. He has extensive management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, has sat on a number of government and industry expert panels.
Brian was the Founder of Aroa (previously Mesynthes) and has been responsible for leading the company’s growth from start-up through to becoming a vertically integrated medical device business with substantial US sales and a developing international presence.
John Pinion has over 25 years of global experience providing executive leadership and expertise in engineering, quality, manufacturing management of biologic, pharmaceutical and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. Mr. Pinion provides leadership for Ultragenyx’s translational sciences functions to include Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance, Validation, and CMC Analytical Development and QC.
As a key member of Ultragenyx’s executive leadership team reporting directly to the organization’s CEO, he also contributes to ongoing business development, clinical development and commercial and strategic planning activities.
In the ten years prior to joining Ultragenyx, Mr. Pinion held roles of increasing responsibility at Genentech (subsequently Roche when Genentech was acquired), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland.
Previous to Genentech, Mr. Pinion spent 17 years in operational and senior leadership roles in Baxter International’s Renal, Bioscience, Parenterals and Device divisions.
John currently sits on the Board of Directors and serves as the Chair of the Audit and Risk Committee of Aroa Biosurgery Ltd, a privately-held soft tissue repair company commercializing regenerative tissue substitutes based in Auckland, New Zealand. He holds a B.S. in Mechanical Engineering from West Virginia University and lives in Northern California with his wife and two sons.
Steven Engle has over 20 years of executive leadership experience with public biotech companies developing breakthrough products in metabolic, autoimmune, oncologic and infectious disease areas. He is the CEO of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Before joining CohBar, Mr. Engle served as CEO of Averigon Consulting, an advisory firm to the life science industry, supporting companies through product partnering, regulatory planning, investor relations and executive management. Previously, he was Chairman and CEO of XOMA Corporation, a leader in the development of therapeutic antibodies and antibody technologies. Prior to XOMA, Mr. Engle served as Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. Earlier, he served as Vice President of Marketing for Cygnus, a drug delivery systems company, where he helped to gain FDA approval and to launch Nicotrol for smoking cessation.
Mr. Engle is Chairman of the Board of Prescient Therapeutics Ltd., a clinical stage oncology company, and a Director of the board of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM, and was a member of the board of the Lupus Foundation of America. Mr. Engle holds M.S.E.E. and B.S.E.E. degrees from the University of Texas with a focus in biomedical engineering.
Mr Diddams has over forty years’ experience as a CFO, CEO and director of both private and publicly listed companies. He leads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed IPO’s, secondary capital raisings and ASX listings in the oil and gas, food and retail, telecommunications, adventure tourism, biotechnology and dental and medical sectors. He is currently a director of Volpara Health Technologies Limited (ASX: VHT) and Surf Lakes Holdings Limited, is Fellow of the Australian Society of CPAs and a Fellow of the Australian Institute of Company Directors.